297 related articles for article (PubMed ID: 29781813)
41. Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.
Xi M; Guo S; Bayin C; Peng L; Chuffart F; Bourova-Flin E; Rousseaux S; Khochbin S; Mi JQ; Wang J
Front Med; 2022 Jun; 16(3):442-458. PubMed ID: 34669156
[TBL] [Abstract][Full Text] [Related]
42. Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia.
Volanakis EJ; Williams RT; Sherr CJ
Blood; 2009 Nov; 114(20):4451-9. PubMed ID: 19759355
[TBL] [Abstract][Full Text] [Related]
43. Dissecting molecular mechanisms of resistance to NOTCH1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts.
Agnusdei V; Minuzzo S; Pinazza M; Gasparini A; Pezzè L; Amaro AA; Pasqualini L; Bianco PD; Tognon M; Frasson C; Palumbo P; Ciribilli Y; Pfeffer U; Carella M; Amadori A; Indraccolo S
Haematologica; 2020 May; 105(5):1317-1328. PubMed ID: 31467126
[TBL] [Abstract][Full Text] [Related]
44. NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia.
Kimura S; Seki M; Yoshida K; Shiraishi Y; Akiyama M; Koh K; Imamura T; Manabe A; Hayashi Y; Kobayashi M; Oka A; Miyano S; Ogawa S; Takita J
Cancer Sci; 2019 Feb; 110(2):784-794. PubMed ID: 30387229
[TBL] [Abstract][Full Text] [Related]
45. Speed of leukemia development and genetic diversity in xenograft models of T cell acute lymphoblastic leukemia.
Poglio S; Lewandowski D; Calvo J; Caye A; Gros A; Laharanne E; Leblanc T; Landman-Parker J; Baruchel A; Soulier J; Ballerini P; Clappier E; Pflumio F
Oncotarget; 2016 Jul; 7(27):41599-41611. PubMed ID: 27191650
[TBL] [Abstract][Full Text] [Related]
46. Notch/CXCR4 Partnership in Acute Lymphoblastic Leukemia Progression.
Tsaouli G; Ferretti E; Bellavia D; Vacca A; Felli MP
J Immunol Res; 2019; 2019():5601396. PubMed ID: 31346528
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia.
Gao J; Van Meter M; Hernandez Lopez S; Chen G; Huang Y; Ren S; Zhao Q; Rojas J; Gurer C; Thurston G; Kuhnert F
Dis Model Mech; 2019 Sep; 12(9):. PubMed ID: 31399482
[TBL] [Abstract][Full Text] [Related]
48. Characterization of transgenic mice expressing cancer-associated variants of human NOTCH1.
Berquam-Vrieze KE; Swing DA; Tessarollo L; Dupuy AJ
Genesis; 2012 Feb; 50(2):112-8. PubMed ID: 21898766
[TBL] [Abstract][Full Text] [Related]
49. Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia.
Mirandola L; Chiriva-Internati M; Montagna D; Locatelli F; Zecca M; Ranzani M; Basile A; Locati M; Cobos E; Kast WM; Asselta R; Paraboschi EM; Comi P; Chiaramonte R
J Pathol; 2012 Apr; 226(5):713-22. PubMed ID: 21984373
[TBL] [Abstract][Full Text] [Related]
50. Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias.
Rakowski LA; Garagiola DD; Li CM; Decker M; Caruso S; Jones M; Kuick R; Cierpicki T; Maillard I; Chiang MY
Cancer Res; 2013 Jan; 73(2):930-41. PubMed ID: 23161489
[TBL] [Abstract][Full Text] [Related]
51. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.
Bandapalli OR; Zimmermann M; Kox C; Stanulla M; Schrappe M; Ludwig WD; Koehler R; Muckenthaler MU; Kulozik AE
Haematologica; 2013 Jun; 98(6):928-36. PubMed ID: 23349303
[TBL] [Abstract][Full Text] [Related]
52. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.
Huang C; Hu X; Wang L; Lü S; Cheng H; Song X; Wang J; Yang J
Cancer Chemother Pharmacol; 2012 Dec; 70(6):801-9. PubMed ID: 22996635
[TBL] [Abstract][Full Text] [Related]
53. T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell.
Serwold T; Hochedlinger K; Swindle J; Hedgpeth J; Jaenisch R; Weissman IL
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18939-43. PubMed ID: 20956329
[TBL] [Abstract][Full Text] [Related]
54. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.
Paganin M; Ferrando A
Blood Rev; 2011 Mar; 25(2):83-90. PubMed ID: 20965628
[TBL] [Abstract][Full Text] [Related]
55. Leukemia-specific delivery of mutant NOTCH1 targeted therapy.
Roti G; Qi J; Kitara S; Sanchez-Martin M; Saur Conway A; Varca AC; Su A; Wu L; Kung AL; Ferrando AA; Bradner JE; Stegmaier K
J Exp Med; 2018 Jan; 215(1):197-216. PubMed ID: 29158376
[TBL] [Abstract][Full Text] [Related]
56. Downregulation of Glutamine Synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1-driven acute lymphoblastic leukemia.
Nguyen TL; Nokin MJ; Terés S; Tomé M; Bodineau C; Galmar O; Pasquet JM; Rousseau B; van Liempd S; Falcon-Perez JM; Richard E; Muzotte E; Rezvani HR; Priault M; Bouchecareilh M; Redonnet-Vernhet I; Calvo J; Uzan B; Pflumio F; Fuentes P; Toribio ML; Khatib AM; Soubeyran P; Murdoch PDS; Durán RV
Mol Oncol; 2021 May; 15(5):1412-1431. PubMed ID: 33314742
[TBL] [Abstract][Full Text] [Related]
57. Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.
Oki T; Kitaura J; Watanabe-Okochi N; Nishimura K; Maehara A; Uchida T; Komeno Y; Nakahara F; Harada Y; Sonoki T; Harada H; Kitamura T
Leukemia; 2012 May; 26(5):1038-45. PubMed ID: 22116551
[TBL] [Abstract][Full Text] [Related]
58. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
Samon JB; Castillo-Martin M; Hadler M; Ambesi-Impiobato A; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Jakubczak J; Randolph S; Cordon-Cardo C; Ferrando AA
Mol Cancer Ther; 2012 Jul; 11(7):1565-75. PubMed ID: 22504949
[TBL] [Abstract][Full Text] [Related]
59. An activating intragenic deletion in NOTCH1 in human T-ALL.
Haydu JE; De Keersmaecker K; Duff MK; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Ferrando A
Blood; 2012 May; 119(22):5211-4. PubMed ID: 22510873
[TBL] [Abstract][Full Text] [Related]
60. CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia.
Jena N; Sheng J; Hu JK; Li W; Zhou W; Lee G; Tsichlis N; Pathak A; Brown N; Deshpande A; Luo C; Hu GF; Hinds PW; Van Etten RA; Hu MG
Leukemia; 2016 May; 30(5):1033-43. PubMed ID: 26707936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
